Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial. This is an ASCO Meeting Abstract from the 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback